ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2024
Potential Effect of Curcumin in Lowering Blood Glucose Level in Streptozotocin-Induced Diabetic Rats.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect of the Consumption of Species from the Zingiberaceae or Berberidaceae Family on Glycemic Profile Parameters: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial.Nutrients · 2024Pooled it
- Chemical constituents in the rhizome of Curcuma longa and the pharmacological importance of curcumin hybrids.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Safety evaluation of an effervescent curcuminoids-ascorbic acid-polysaccharide-β-cyclodextrin (CUR-A-Poly-β-CD) inclusion complex powder in healthy volunteers: A non-placebo-controlled pilot study.Toxicology reports · 2026Article
- Unraveling the Systems Biology of Curcumin: A Mini-review of its Anti-diabetic Potential through Network Pharmacology.Cell biochemistry and biophysics · 2026Review
- A combined network pharmacology and experimental approach to investigate the mechanisms of curcumin on diabetes through the adipocytokine signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Curcumin alleviates diabetic encephalopathy by attenuating cerebral microvascular ferroptosis: involvement of KEAP1/Nrf2 signalling.Frontiers in pharmacology · 2026Article
- Article
- Investigation of the antidiabetic efficacy of Diabepat Kadha in type 2 diabetic Sprague-Dawley rats: modulation of GLUT4 expression as a molecular target.Journal of molecular histology · 2025Article
- Natural Deep Eutectic Solvents Combined with Supercritical Carbon Dioxide for the Extraction of Curcuminoids from Turmeric.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The prevalence of diabetes mellitus has significantly increased, with 537 million individuals living with diabetes in 2021. Curcumin, a natural compound present in turmeric, has anti-inflammatory and antioxidant properties that aid in controlling diabetes. Curcumin can lower blood glucose levels, increase pancreatic cell function, and reduce insulin resistance. The pathophysiology of diabetes involves oxidative stress and endoplasmic reticulum stress, which can lead to cell death. This study aimed to evaluate the antidiabetic activity of curcumin in rats by administering it for a month and evaluating pancreatic tissue histology. Patients and Methods: STZ-induced diabetic rats were fed a high-fat diet containing glibenclamide, 200 mg/kg body weight (BW) curcumin, 400 mg/kg BW curcumin, or a placebo for 4 weeks. After intervention, blood glucose levels were measured, and the pancreatic tissue was examined. Blood glucose levels were measured at 0, 2, 4, 6, and 8 h. Results: One-way ANOVA was performed to measure the mean difference among the groups at 0, 2, 4, 6, and 8 h of observation, which reported a statistically significant difference (p < 0.05). The blood glucose levels decreased after 4 h in the group receiving curcumin. Histological evaluation of the pancreas showed slight hydropic degeneration after 4 weeks of curcumin treatment. Conclusion: Our study indicates that curcumin has a beneficial effect in diabetic rats by reducing blood glucose levels and a protective effect on the pancreas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.